Automation and Increased Accuracy for Hormone Receptors in Breast Cancer
Join Visiopharm next week for a webinar titled, “Hormone Receptors in Breast Cancer: Automation and Increased Accuracy” on September 16, 2014 at 4 PM CET / 10 AM EST / 7 AM PST. Estrogen (ER) and progesterone (PR; PgR) evaluation is routinely used for clinical breast cancer assessment. While ER is known to have a predictive value to predict patient response to hormonal therapy, PR is less established. Robust, reproducible, and accurate assessment of hormone receptors (ER and PR) is essential for making optimal treatment decisions in breast cancer: Both false-negative and false-positive readings can have serious implications for the patient.
For both ER and PR, several IHC semi-quantitative scoring systems have been developed. McCarty’s H-score, based on percentage of positive cells by a factor representing the intensity of immunoreactivity, the immunoreactive Remmele score (IRS), which is a product of the proportion score and an intensity score, and the Allred (modified quick score), which uses the same intensity score as the H-score and IRS system but adds the proportion of cells staining. Common for all three scoring methods is a subjective evaluation of intensity, which is known to be subject to reader variation.
Furthermore, the use of sensitive staining protocols has demonstrated a tendency to induce positive reaction within stroma making areas appear tumor like. This especially occurs for sensitive antibodies also causing the expression to become bimodal.
About Our Speaker
Martin Kristensson is Senior Application Specialist & Project Manager in Digital Pathology. He has been with Visiopharm for the last 3 years where he has worked with almost all aspects of our business.
